Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
4.760
-0.230 (-4.61%)
At close: Apr 28, 2026, 4:00 PM EDT
4.730
-0.030 (-0.63%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 5.04% from the current stock price of 4.76.
Analyst Consensus: Sell
* Price targets were last updated on Jan 21, 2026.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock from 2 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 0 | 0 | 0 | 0 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 4 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Freedom Broker | Freedom Broker | Strong Buy → Strong Sell Downgrades $16 → $4 | Strong Buy → Strong Sell | Downgrades | $16 → $4 | -15.97% | Jan 21, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $25 → $6 | Strong Buy → Hold | Downgrades | $25 → $6 | +26.05% | Jan 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 → $25 | Strong Buy | Maintains | $17 → $25 | +425.21% | Dec 19, 2025 |
| Freedom Broker | Freedom Broker | Strong Sell Maintains $13 → $16 | Strong Sell | Maintains | $13 → $16 | +236.13% | Jul 28, 2025 |
| Freedom Broker | Freedom Broker | Strong Sell Maintains $11 → $13 | Strong Sell | Maintains | $11 → $13 | +173.11% | May 23, 2025 |
Financial Forecast
Revenue This Year
31.86M
from 120.77M
Decreased by -73.62%
Revenue Next Year
31.38M
from 31.86M
Decreased by -1.49%
EPS This Year
-1.15
from 2.57
EPS Next Year
-1.29
from -1.15
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 63.0M | 86.1M | |||
| Avg | 31.9M | 31.4M | |||
| Low | 11.5M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -47.8% | 170.3% | |||
| Avg | -73.6% | -1.5% | |||
| Low | -90.5% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.85 | -1.11 | |||
| Avg | -1.15 | -1.29 | |||
| Low | -1.42 | -1.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.